華潤醫藥(03320.HK)旗下華潤三九與深圳灣實驗室聯合研究中心揭牌
華潤醫藥(03320.HK)宣布,旗下華潤三九-深圳灣實驗室聯合研究中心揭牌儀式,暨華潤集團與深圳灣實驗室戰略合作協議簽約日前於惠州舉行。
根據協議,雙方將充分發揮彼此優勢資源,圍繞生物醫藥、人工智能、新材料和醫療器械等領域開展深入合作,為粵港澳大灣區產業提供強大的科學研究和成果轉化支持;創新科研合作模式,成立聯合研究中心,通過組建產學研團隊開展技術攻關等多種方式共同推進關鍵技術研究與創新。
新成立的聯合研究中心將由集團旗下華潤三九、華潤科學技術研究院以及深圳灣實驗室坪山生物醫藥研發轉化中心三方共同建設並開展聯合技術攻關。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.